Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy

NCT03914300 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03914300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03914300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 10, 2020
Completion date
December 17, 2026
Enrollment
11 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid gland carcinoma, follicular variant thyroid gland papillary carcinoma, poorly differentiated thyroid gland carcinoma, refractory differentiated thyroid gland carcinoma, refractory thyroid gland carcinoma, tall cell variant thyroid gland papillary carcinoma, thyroid gland follicular carcinoma, thyroid gland oncocytic carcinoma, thyroid gland papillary carcinoma